

# ESMO PRECEPTORSHIP PROGRAMME

## COLORECTAL CANCER

Multidisciplinary management, standards of care  
and future perspectives

**Valencia, Spain**  
**17-18 May 2019**

<b>CO-CHAIRS:</b>	Andrés Cervantes, Spain Dirk Arnold, Portugal	<b>SPEAKERS:</b>	Regina Beets-Tan, Netherlands Frédéric Bibeau, France Chiara Cremolini, Italy Michel Ducreux, France Demetris Papamichael, Cyprus Luis Sabater, Spain Francesco Sclafani, Belgium Elizabeth Smyth, United Kingdom Carlos Vaz, Portugal
-------------------	--	------------------	--

### LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprognostic factors
- To learn about the management of patients after progression, side-effects of treatments and in special situations

### Friday, 17 May 2019

<b>09:00-09:15</b> 15'	<b>Welcome and introduction</b>	<b>Andrés Cervantes, ES</b>
<b>09:15-10:55</b> 100'	<b>SESSION 1</b> <b>Early colorectal cancer</b>	<b>Chair:</b> <b>Francesco Sclafani, BE</b>
20'	The point of view of the pathologist - Quality and rules of a good pathology report - Histo-prognostic factors: Number of lymph nodes, neural/lymphatic invasion, lymphocytic infiltration, MSH expression	Frédéric Bibeau, FR
20'	Optimal loco-regional staging for rectal cancer	Regina Beets-Tan, NL
20'	State-of-the-art: Standard(s) of surgical practice for resectable colorectal cancer (special issues on rectal cancer, laparoscopy, transanal TME and robotic-assisted surgery)	Carlos Vaz, PT
20'	State-of-the-art: Standard(s) of care in pre-operative treatment for rectal cancer	Francesco Sclafani, BE
20'	The role of chemotherapy of localized rectal cancer	Andrés Cervantes, ES
<b>10:55-11:25</b>	<b>Coffee break</b>	

<b>11:25-13:25</b> 120'	<b>SESSION 2</b> <b>Adjuvant settings of colorectal cancer</b>	<b>Chair:</b> <b>Dirk Arnold, PT</b>
30'	RAS, BRAF: Microsatellite instability and other molecular markers – How useful are they? Pitfalls in diagnostic?	Frédéric Bibeau, FR
30'	Adjuvant treatment for colon cancer II and III	Michel Ducreux, FR
30'	Adjuvant treatment for elderly patients: How to address it	Demetris Papamichael, CY
3x10'	3 x Participant clinical case discussion	Faculty

<b>13:25-14:25</b>	<b>Lunch</b>
--------------------	--------------

<b>14:25-16:20</b> 115'	<b>SESSION 3</b> <b>Metastatic colorectal cancer, liver limited metastases</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
20'	Review of the ESMO Consensus Conference on metastatic colorectal cancer - Basic strategies and groups (RASwt/mut, BRAF mut)	Chiara Cremolini, IT
20'	Chemotherapy and targeted agents in 1 <sup>st</sup> line	Chiara Cremolini, IT
30'	Oligometastatic colorectal cancer: What to know about and how to treat it	Dirk Arnold, PT
45'	Presentation of three challenging clinical cases and faculty discussion	Andrés Cervantes, ES Faculty

<b>16:20-16:50</b>	<b>Coffee break</b>
--------------------	---------------------

<b>16:50-18:25</b> 95'	<b>SESSION 4</b> <b>Metastatic colorectal cancer: Special clinical situations</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
20'	How to integrate surgery in the treatment of patients with liver-only metastatic disease	Luis Sabater, ES
15'	How to deal with elderly patients or individuals with comorbidities	Demetris Papamichael, CY
15'	How to deal with synchronous primary and liver metastases	Luis Sabater, ES
15'	How to deal with patients with isolated peritoneal metastases	Michel Ducreux, FR
3x10'	3 x Participant clinical case discussion	Faculty

<b>20:30</b>	<b>Dinner</b>
--------------	---------------

## Saturday, 18 May 2019

<b>08:30-10:00</b> 90'	<b>SESSION 5</b> <b>Metastatic colorectal cancer: Maintenance and further lines</b>	<b>Chair:</b> <b>Dirk Arnold, PT</b>
30'	The role of maintenance treatment, appropriate endpoints according to ESMO Consensus	Dirk Arnold, PT
30'	What to do after 1 <sup>st</sup> line failure	Dirk Arnold, PT
30'	Management of treatment related side effects <ul style="list-style-type: none"> <li>- GI-toxicity</li> <li>- Neuropathy</li> <li>- Skin toxicity</li> <li>- Hypertension</li> <li>- Hand-foot syndrome</li> </ul>	Michel Ducreux, FR
10:00-10:30 Coffee break		
<b>10:30-11:00</b> 30'	<b>SPECIAL LECTURE</b> <b>Immunotherapy in gastrointestinal cancers</b>	<b>Chair:</b> <b>Dirk Arnold, PT</b>
30'	Immunotherapy in gastrointestinal cancers	Elizabeth Smyth, UK
<b>11:00-11:20</b> 20'	<b>SESSION 6</b> <b>Anal canal tumours</b>	<b>Chair:</b> <b>Francesco Sclafani, BE</b>
20'	Standard of care for anal canal squamous carcinomas	Francesco Sclafani, BE
<b>11:20-11:50</b> 30'	<b>SESSION 7</b> <b>Metastatic colorectal cancer: Case discussion</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
3x10'	3 x Participant clinical case discussion	Faculty
<b>11:50-12:05</b> 15'	<b>Conclusion and farewell</b>	<b>Andrés Cervantes, ES</b>
12:05-13:05 Lunch		

**Note:** Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion